Reshaping the HIV treatment and prevention landscape
Strengthening
leadership in
vaccines
High single digit % sales CAGR 2021-26
Global reach and commercial execution
World class manufacturing capability and scale
Industry-leading pipeline, FiC / BiC potential, 16 Phase 2/3 assets
Unrivalled portfolio and breadth of technology platforms
Advancing COVID solutions
5 planned new launches by 2026, including £multi-billion RSV opportunity
Doubling Shingrix revenues in 5 years
Ambition to double meningitis sales and flu sales in next 10 years
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for
the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are
excluded from the above.
Shingrix, meningitis and flu revenues from 2020 base
FiC First-in-Class; BiC Best-in-Class
57View entire presentation